Ratings Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.26 ^USD	-2.41%		-8.04%	-41.49%

Apr. 24	EU Grants Conditional Marketing Approval for CSL Vifor, Travere’s Kidney Disease Treatment	MT
Apr. 24	Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Revenue estimates are regularly revised downwards for the current and coming years.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
TRAVERE THERAPEUTICS, INC.	-41.49%	400M	B-
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B	B+
ARGENX SE	+1.69%	22.15B	B
BIONTECH SE	-17.37%	21.02B	B+
GENMAB A/S	-9.30%	18.15B	A-
WUXI APPTEC CO., LTD.	-41.01%	16.73B	A-
BEIGENE, LTD.	-14.85%	16.05B	B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B	C+
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes